Fortress Biotech, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Collaboration and Stock Purchase Agreements (Narrative) (Details)

Collaboration and Stock Purchase Agreements (Narrative) (Details) $ / shares in Units, $ in Thousands, shares in Millions						1 Months Ended	12 Months Ended
	Oct. 06, 2021 USD ($)	Oct. 05, 2021 USD ($)	Feb. 24, 2021 USD ($) Milestone	Feb. 08, 2019 USD ($) $ / shares shares	Nov. 12, 2018	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Collaboration revenue							$ 5,389	$ 0
Accumulated deficit							(547,463)	(482,760)
Cash and cash equivalents							305,744	233,351
Cyprium [Member] \| Sentynl Therapeutics, Inc [Member]
Upfront fees payment			$ 8,000
Payments of milestones			$ 12,000
Percentage of ownership over any FDA priority review voucher			100.00%
Number of net sales milestones \| Milestone			5
Number of development milestones \| Milestone			2
Collaboration revenue							$ 5,400	$ 0
Caelum [Member] \| AstraZeneca [Member]
Percentage of proceeds from option exercise		42.40%				42.40%
Option exercise price		$ 150,000				$ 150,000
Proceeds from option exercise		$ 56,900				$ 56,900
Percentage of escrow holdback		10.00%
Revenue from collaboration agreement		$ 148,600
Maximum [Member] \| Caelum [Member] \| AstraZeneca [Member]
Deconsolidation of consolidated partner company, contingent payment	$ 350,000
Revenue from collaboration agreement		$ 350,000
SPMA [Member] \| Avenue [Member] \| InvaGen [Member]
Sale of stock, ownership percentage after the transaction					33.30%
FDA approval of the NDA [Member] \| Cyprium [Member] \| Sentynl Therapeutics, Inc [Member]
Payments of milestones			$ 9,000
Achievement of Certain Sales Milestones [Member] \| Cyprium [Member] \| Sentynl Therapeutics, Inc [Member]
Payments of milestones			255,000
Strategic Transaction, First Stage [Member] \| SPMA [Member] \| Avenue [Member] \| InvaGen [Member]
Sale of stock, number of shares issued \| shares				5.8
Stock offering, price per share \| $ / shares				$ 6.00
Sale of Stock, Consideration Received on Transaction				$ 35,000
Sale of stock, ownership percentage after the transaction				33.30%
Completion of Clinical Development Milestones [Member] \| Cyprium [Member] \| Sentynl Therapeutics, Inc [Member]
Payments of milestones			$ 3,000